This press release shall not be published, transmitted, or distributed directly or indirectly to the United States of America, Canada,…
Categorie
2021
MaaT Pharma awarded non-dilutive funding of EURO 1.9 million for its “MEPA” project through the France Relance “Resilience” program This…
July 20, 2021
Independent Data Safety and Monitoring Board (DSMB) recommends continuing study as planned and initiating dosing of fourth patient cohort CIMON…
June 28, 2021
The trial of the autologous microbial therapy, MaaT011, met its primary endpoints through demonstration of restored gut microbiota balance and…
May 25, 2021
L’essai de la thérapie autologue de restauration du microbiote, MaaT011, a atteint ses objectifs principaux en démontrant la restauration de…
May 25, 2021
Communiqué de presse Lancement de l’Alliance Promotion Microbiote Le 29 mars 2021 – L’Alliance Promotion Microbiote est lancée : fruit de…
March 29, 2021
Study meets primary and key secondary objectives with positive impact and favorable overall safety profile in 21 heavily pre-treated and…
March 17, 2021
Data from 29 patients in the company’s early access program with MaaT013 as a treatment for gastrointestinal acute Graft-versus-Host Disease…
March 11, 2021
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.